Table 1.
Demographics and patient characteristics
| GL (n = 196) | BIL (n = 192) | |
|---|---|---|
| Age (years) | 56.9 ± 9.6 | 57.9 ± 10.0 |
| Male, n (%) | 106 (54.1) | 111 (57.8) |
| Weight (kg) | 69.7 ± 12.6 | 70.0 ± 12.7 |
| Body mass index (kg/m2) | 26.0 ± 3.7 | 26.2 ± 3.6 |
| Duration of diabetes (years) | 11.8 ± 6.2 | 12.5 ± 6.5 |
| Region, n (%) | ||
| Japan | 102 (52.0) | 103 (53.6) |
| South Korea | 52 (26.5) | 49 (25.5) |
| Taiwan | 42 (21.4) | 40 (20.8) |
| Oral antihyperglycemic medications, n (%) | ||
| Biguanides | 167 (85.2) | 164 (85.4) |
| Sulfonylurea | 158 (80.6) | 159 (82.8) |
| DPP‐4 inhibitor | 139 (70.9) | 129 (67.2) |
| α‐Glucosidase inhibitor | 32 (16.3) | 27 (14.1) |
| Thiazolidinediones | 22 (11.2) | 28 (14.6) |
| Oral antihyperglycemic medications during treatment, n (%) | ||
| 2 | 75 (38.3) | 73 (38.0) |
| 3 | 108 (55.1) | 108 (56.3) |
| ≥4 | 13 (6.6) | 11 (5.7) |
| Lipid‐lowering medications, n (%) | 118 (60.2) | 114 (59.4) |
| Hypertension, n (%) | 125 (63.8) | 120 (62.5) |
All patients were Asian. Data are mean ± standard deviation unless otherwise noted. BIL, basal insulin peglispro; DPP‐4, dipeptidyl peptidase‐4; GL, glargine; SD, standard deviation.